Avalo Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
| ☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|---|
| for the quarterly period ended March 31, 2025 | |
| OR | |
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
COMMISSION FILE NUMBER:001-37590
AVALO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware(State of incorporation) | 45-0705648(I.R.S. Employer Identification No.) |
|---|---|
| 1500 Liberty Ridge Drive, Suite 321Wayne, Pennsylvania 19087(Address of principal executive offices) | (410) 522-8707(Registrant’s telephone number,including area code) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.001 par value | AVTX | Nasdaq Capital Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ |
|---|---|
| Non-accelerated filer ☑ | Smaller reporting company ☑ |
| Emerging growth company ☐ | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes☐ No☑
As of May 7, 2025, the registrant had 10,827,620 shares of common stock outstanding.
AVALO THERAPEUTICS, INC.
FORM 10-Q
For the Quarter Ended March 31, 2025
TABLE OF CONTENTS
| Page | |||||
|---|---|---|---|---|---|
| PART I. | FINANCIAL INFORMATION | ||||
| Item 1. · Financial Statements | |||||
| a) | Condensed Consolidated Balance Sheets as of March 31, 2025 (Unaudited) and December 31, 2024 | 3 | |||
| b) | Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) for the Three Months Ended March 31, 2025 and 2024 | 5 | |||
| c) | Condensed Consolidated Statements of Mezzanine and Stockholders’ Equity (Unaudited) for the Three Months Ended March 31, 2025 and 2024 | 6 | |||
| d) | Condensed Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2025 and 2024 | 7 | |||
| e) | Notes to Unaudited Condensed Consolidated Financial Statements | 8 | |||
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 30 | |||
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 36 | |||
| Item 4. | Controls and Procedures | 36 | |||
| PART II. | OTHER INFORMATION | ||||
| Item 1. | Legal Proceedings | 37 | |||
| Item 1A. | Risk Factors | 37 | |||
| Item 6. | Exhibits | 38 | |||
| SIGNATURES | 39 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.